Literature DB >> 3309489

Monoamines in autism: an update of neurochemical research on a pervasive developmental disorder.

G M Anderson1.   

Abstract

Recent neurochemical studies of norepinephrine (NE), dopamine (DA), and serotonin (5HT) in autism are reviewed. Most studies of the catecholamines, their metabolites, and associated enzymes have not found differences between autistic and normal subjects. However, a robust increase in platelet 5HT has been well replicated and characterized. Studies on the possible causes of the increased platelet 5HT in autism suggest that an alteration in platelet physiology is the cause of the increase. Future directions for research on the platelet are discussed as are other potentially fruitful methods for examining monoamine functioning in autism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3309489

Source DB:  PubMed          Journal:  Med Biol        ISSN: 0302-2137


  4 in total

1.  No association of the norepinephrine transporter gene (SLC6A2) and cognitive and behavioural phenotypes of patients with autism spectrum disorder.

Authors:  Subin Park; Jong-Eun Park; Soo-Churl Cho; Bung-Nyun Kim; Min-Sup Shin; Jae-Won Kim; In Hee Cho; Soon Ae Kim; Mira Park; Tae-Won Park; Jung-Woo Son; Un-Sun Chung; Hee Jeong Yoo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-01-01       Impact factor: 5.270

2.  Hyperserotonemia in adults with autistic disorder.

Authors:  Dubravka Hranilovic; Zorana Bujas-Petkovic; Renata Vragovic; Tomislav Vuk; Karlo Hock; Branimir Jernej
Journal:  J Autism Dev Disord       Date:  2006-12-13

Review 3.  Selective Serotonin Reuptake Inhibitor Use during Pregnancy and the Risk of Autism Spectrum Disorders: A Review.

Authors:  Takoua Boukhris; Anick Bérard
Journal:  J Pediatr Genet       Date:  2015-06

4.  Hyperserotonemia in autism: activity of 5HT-associated platelet proteins.

Authors:  Dubravka Hranilović; Zorana Bujas-Petković; Maja Tomicić; Tatjana Bordukalo-Niksić; Sofia Blazević; Lipa Cicin-Sain
Journal:  J Neural Transm (Vienna)       Date:  2009-02-17       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.